SC 56631

Drug Profile

SC 56631

Latest Information Update: 01 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacia Corporation
  • Class Osteoporosis therapies
  • Mechanism of Action GPIIb-IIIa antagonists; Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Postmenopausal osteoporosis
  • No development reported Thrombosis

Most Recent Events

  • 05 Apr 2000 Monsanto has merged with Pharmacia & Upjohn to form Pharmacia Corporation
  • 28 Feb 2000 Suspended-Unspecified Phase in Postmenopausal osteoporosis in USA (IV)
  • 02 Mar 1998 Preclinical development for Thrombosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top